Pharma China, the most influential English media and business intelligence service covering China's pharmaceutical sector, is pleased to announce the addition of Dr. Vivian Chen to its prestigious advisory board, which is composed of 13 leading China healthcare experts and veteran executives.

Vivian is now Director of Public Policy and Center of Excellence for China with Becton Dickinson. Until recently, she was Director of Healthcare Economic Policy at RDPAC. Prior to that, She had been a policy economist with 15 years of professional experience in public policy, international economic development, industrial growth analysis, social security reform and healthcare financing at the World Bank and US Department of Labor in Washington, DC. since 1994. After returning to China in 2003, she provided consulting and research services to the World Bank, Asian Development Bank, International Labor Organization, USAID, as well as IBM, Accenture and the Conference Board. Her previous focus at RDPAC encompassed healthcare reform policy, particularly with regard to China’s pharmaceutical policy evolving of new drug approval, hospital procurement, drug distribution, pricing, medical insurance and drug reimbursement system. She led analytic and advocacy efforts for RDPAC's Healthcare Policy Expert Committee for R&D industry, and has built strong evidence-based research practice for RDPAC to effectively support industry advocacy programs.

Pharma China's Advisory Board is consisted of the following 13 industry leaders (in the order of last name):

Dr Rob Bryant - Principal, Brychem Business Consulting.

Peter Chua – President, Association of Hong Kong Healthcare Professionals; Member, the Pharmacy & Poisons Board of the Hong Kong Government; President, Huatai Pharmaceutical Ltd., Hong Kong; Director, Beijing United Pharmaceutical Ltd.; Justice of Peace (HK); and former President, Hong Kong Pharmaceutical Society.

Dr. Vivian Chen – Director of Public Policy and Center of Excellence for China, Becton Dickinson; and former Director of Healthcare Economic Policy, RDPAC.

Stanley Lau – President, China Biological Products Inc.; former GM - Baxter China; former GM - Schering Plough China; former GM Asia – Searle/Pharmacia; and former GM MSD - Taiwan.

Simon Luo – Director of Operations and Country Manager, IMS Greater China; Board Director, Chinese Hospital Association; Senior Advisor, National Institute of Hospital Administration under the Ministry of Health; Advisor, China Association of Pharmaceutical Commerce; and Advisor, China Association of Chain Drug Stores.

Robert Pollard – Managing Director Asia Pacific, P\S\L Group Market Research; and former Director Synovate Healthcare China.

Dr. Xiaomei Li Reckford, Vice President, China Strategic Growth, Quintiles Transnational Corporation; Former CEO, Quintiles Greater China.

Dr. Jiaxiang Shen - Senior Fellow, Chinese Academy of Engineering; Honorary Chairman, the Pharmacy College of Tianjin University; and advisor to many Chinese government agencies; and former Deputy Chief Engineer, State Pharmaceutical Administration of China and Director, National Institutes for Pharmaceutical R&D.

Peter Scheuer – Head of Legal Affairs, Bayer Healthcare China; and Former Executive Director, R&D-based Pharmaceutical Association in China (RDPAC).

Dr. Yan Yan L Starkey - Director, New Product Research China Liaison at GlaxoSmithKline Consumer Healthcare.

Dr. Dong Xie – Chairman and CEO, Frontier Biotechnology Ltd.

Cheryl Q. Xu – President, Aquila Health Consulting and Advisor on China, Pharmaceutical Research and Manufacturers of America (PhRMA).

Dr. Weiping Yang – Chairman and CEO, Fresenius Kabi China; and Director, RDPAC.